Drugs / ADEL-Y01
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06247345 Comparator | Feb 2024 → Jan 2026 | Alzheimer disease | Alzheimer's Disease Expert Lab (ADEL), Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADEL Y-01 | “This arm represents the group receiving ADEL Y-01 antibody at a dose of 2.5mg/Kg in SAD cohort 1.” NCT06247345 ↗ |
| Action | Inhibit | “thus inhibiting aggregation and propagation of tau seeds” NCT06247345 ↗ |
| Modality | Monoclonal antibody | “recombinant IgG1 class type monoclonal humanized antibody” NCT06247345 ↗ |
| Route | Intravenous | “multiple IV doses of ADEL-Y01 administered every 2 weeks” NCT06247345 ↗ |